Manufacturer record
Trizal Formulation: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Trizal Formulation (Himachal Pradesh) were declared Not of Standard Quality in January 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: TV-880012, Voglibose Tablets IP (0.2 mg) (exp Jan 2024). RDTL Chandigarh (CDSCO lab) found it not of standard quality: Disintegration. Listed in the January 2023 alert.
Records by type
2 records linked to Trizal Formulation in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Voglibose Tablets IP (0.2 mg) | Batch TV-880012Mfg Feb 2022 · Exp Jan 2024 | DisintegrationDisintegration | RDTL ChandigarhCDSCO lab | Jan 2023 |
| Loose yellow colored Tablets (Purported to contain Rosuvastatin 10 mg) | Batch Not applicableMfg ? · Exp ? | Assay of RosuvastatinAssay | RDTL ChandigarhState lab | Jan 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.